FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281733227> ?p ?o ?g. }

• W4281733227 abstract "Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent threat to public health requiring the development of novel therapies. TP0586532 is a novel non-hydroxamate LpxC inhibitor that inhibits the synthesis of lipopolysaccharides, which are components of the outer membranes of Gram-negative bacteria. Based on the mechanism of action of TP0586532, we hypothesized that it might enhance the antibacterial activity of other antibiotics by increasing the permeability of the outer bacterial membrane. The combination of TP0586532 with meropenem, amikacin, cefepime, piperacillin, and tigecycline showed synergistic and additive effects against carbapenem-susceptible Klebsiella pneumoniae and Escherichia coli. Checkerboard experiments against 21 carbapenem-resistant K. pneumoniae and E. coli strains (13 blaKPC+, 5 blaNDM-1+, 2 blaVIM+, and 1 blaIMP+) showed that the combination of TP0586532 with meropenem yielded synergistic and additive effects against 9 and 12 strains, respectively. In a time-kill assay examining 12 CRE strains, synergistic effects were observed when TP0586532 was combined with meropenem against many of the strains. A membrane permeability assay using ethidium bromide (EtBr) was performed to investigate the mechanism of the potentiating effect. TP0586532 increased the influx of EtBr into a CRE strain, suggesting that TP0586532 increased membrane permeability and facilitated intracellular access for the antibiotics. Our study demonstrates that TP0586532 potentiates the in vitro antibacterial activity of meropenem against CRE. Combination therapy consisting of TP0586532 and meropenem has potential as a treatment for CRE infections. IMPORTANCE Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent public health threat, as therapeutic options are limited. TP0586532 is a novel LpxC inhibitor that inhibits the synthesis of lipopolysaccharides in the outer membranes of Gram-negative bacteria. Here, we demonstrated the potentiating effects of TP0586532 on the antibacterial activity of meropenem against CRE harboring various types of carbapenemase genes (blaKPC+, blaNDM-1+ blaVIM+, and blaIMP+). TP0586532 also augmented the bactericidal effects of meropenem against CRE strains, even against those with a high level of resistance to meropenem. The potentiating effects were suggested to be mediated by an increase in bacterial membrane permeability. Our study revealed that a combination therapy consisting of TP0586532 and meropenem has the potential to be a novel therapeutic option for CRE infections." @default.
• W4281733227 created "2022-06-13" @default.
• W4281733227 creator A5026048572 @default.
• W4281733227 creator A5039271936 @default.
• W4281733227 creator A5040030752 @default.
• W4281733227 creator A5043111366 @default.
• W4281733227 creator A5069950515 @default.
• W4281733227 date "2022-06-29" @default.
• W4281733227 modified "2023-09-26" @default.
• W4281733227 title "TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on <i>In Vitro</i> Activity of Meropenem against Carbapenem-Resistant Enterobacteriaceae" @default.
• W4281733227 cites W1471870375 @default.
• W4281733227 cites W1547203214 @default.
• W4281733227 cites W1580202151 @default.
• W4281733227 cites W1833417126 @default.
• W4281733227 cites W1895129045 @default.
• W4281733227 cites W2013883719 @default.
• W4281733227 cites W2033990028 @default.
• W4281733227 cites W2042164350 @default.
• W4281733227 cites W2095203833 @default.
• W4281733227 cites W2109954853 @default.
• W4281733227 cites W2131784175 @default.
• W4281733227 cites W2143778802 @default.
• W4281733227 cites W2154642444 @default.
• W4281733227 cites W2157925105 @default.
• W4281733227 cites W2159024207 @default.
• W4281733227 cites W2164697816 @default.
• W4281733227 cites W2166505398 @default.
• W4281733227 cites W2196782563 @default.
• W4281733227 cites W2468787626 @default.
• W4281733227 cites W2473016454 @default.
• W4281733227 cites W2515950493 @default.
• W4281733227 cites W2551729802 @default.
• W4281733227 cites W2559621415 @default.
• W4281733227 cites W2607050795 @default.
• W4281733227 cites W2618911885 @default.
• W4281733227 cites W2770745290 @default.
• W4281733227 cites W2886232746 @default.
• W4281733227 cites W2895593384 @default.
• W4281733227 cites W2915553362 @default.
• W4281733227 cites W2929890274 @default.
• W4281733227 cites W2959149559 @default.
• W4281733227 cites W2966447251 @default.
• W4281733227 cites W2987874251 @default.
• W4281733227 cites W3014723075 @default.
• W4281733227 cites W3016555942 @default.
• W4281733227 cites W3116314579 @default.
• W4281733227 cites W3151150819 @default.
• W4281733227 cites W3215078756 @default.
• W4281733227 cites W4205985016 @default.
• W4281733227 cites W4210744533 @default.
• W4281733227 cites W4255231775 @default.
• W4281733227 doi "https://doi.org/10.1128/spectrum.00828-22" @default.
• W4281733227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35647694" @default.
• W4281733227 hasPublicationYear "2022" @default.
• W4281733227 type Work @default.
• W4281733227 citedByCount "3" @default.
• W4281733227 countsByYear W42817332272023 @default.
• W4281733227 crossrefType "journal-article" @default.
• W4281733227 hasAuthorship W4281733227A5026048572 @default.
• W4281733227 hasAuthorship W4281733227A5039271936 @default.
• W4281733227 hasAuthorship W4281733227A5040030752 @default.
• W4281733227 hasAuthorship W4281733227A5043111366 @default.
• W4281733227 hasAuthorship W4281733227A5069950515 @default.
• W4281733227 hasBestOaLocation W42817332271 @default.
• W4281733227 hasConcept C104317684 @default.
• W4281733227 hasConcept C146587185 @default.
• W4281733227 hasConcept C2776685102 @default.
• W4281733227 hasConcept C2777027569 @default.
• W4281733227 hasConcept C2777050379 @default.
• W4281733227 hasConcept C2777058267 @default.
• W4281733227 hasConcept C2778910516 @default.
• W4281733227 hasConcept C2779375183 @default.
• W4281733227 hasConcept C2779631663 @default.
• W4281733227 hasConcept C2992270614 @default.
• W4281733227 hasConcept C41625074 @default.
• W4281733227 hasConcept C501593827 @default.
• W4281733227 hasConcept C547475151 @default.
• W4281733227 hasConcept C55493867 @default.
• W4281733227 hasConcept C86803240 @default.
• W4281733227 hasConcept C89423630 @default.
• W4281733227 hasConcept C94665300 @default.
• W4281733227 hasConceptScore W4281733227C104317684 @default.
• W4281733227 hasConceptScore W4281733227C146587185 @default.
• W4281733227 hasConceptScore W4281733227C2776685102 @default.
• W4281733227 hasConceptScore W4281733227C2777027569 @default.
• W4281733227 hasConceptScore W4281733227C2777050379 @default.
• W4281733227 hasConceptScore W4281733227C2777058267 @default.
• W4281733227 hasConceptScore W4281733227C2778910516 @default.
• W4281733227 hasConceptScore W4281733227C2779375183 @default.
• W4281733227 hasConceptScore W4281733227C2779631663 @default.
• W4281733227 hasConceptScore W4281733227C2992270614 @default.
• W4281733227 hasConceptScore W4281733227C41625074 @default.
• W4281733227 hasConceptScore W4281733227C501593827 @default.
• W4281733227 hasConceptScore W4281733227C547475151 @default.
• W4281733227 hasConceptScore W4281733227C55493867 @default.
• W4281733227 hasConceptScore W4281733227C86803240 @default.
• W4281733227 hasConceptScore W4281733227C89423630 @default.
• W4281733227 hasConceptScore W4281733227C94665300 @default.
• W4281733227 hasIssue "3" @default.
• W4281733227 hasLocation W42817332271 @default.

• next